Skip to main content
CYTK logo

CYTK · Cytokinetics Inc · Documents

Track CYTK — free
Market Cap
$7.07B
Shares
139.30M
Volume · Nov 20 1.43M Avg daily vol (3M) 2.01M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $88.04M up 376.6% 10-K filed Feb 26, 2026 Quarterly report FY2026 Q3 Revenue $47.56M up 2356.5% 10-Q filed Nov 4, 2026 Latest results MYQORZO net product revenue reaches $44.5 million 8-K filed Nov 4, 2026 Earnings call Q3 2026 earnings call Held Nov 4, 2026
2026
Nov 16
Investor event
FDA permits Maple HCM data for expanded MyCorso label

Cytokinetics reported strong MyCorso commercialization, FDA approval to include Maple HCM data in an expanded label, and an Acacia SNDA submission planned this quarter. Germany reached over 50% new-to-brand share, and cash totaled $1.6 billion at quarter-end.

6 source passages
So I think all of this combined underscores cytokinetics as doing what it said it was going to do. Executing well on the commercialization of MyCorso, expanding the label to include Maple HCM, and next up is, as we guided, submission of an SNDA inclusive of Acacia data, and as that could be factoring into label next year. This morning, we announced that the U.S. FDA has... Approved our FNDA to be enabling of data from Maple HCM to be included in an expanded label for Mycorso. Well, so we are on track to submit our supplemental NDA this quarter, as we guided to on our last earnings call, and the review process will take place. Germany is already over 50% in new-to-brand share just a few months into launch, and they've had three months in a row of that level of performance. As you know, we maintain a very strong balance sheet, $1.6 billion at the end of the last quarter. Open the document at this passage
Nov 10
Investor event
Revenue rose 76% as new-to-brand share neared 45%

Cytokinetics reported revenue up 76% versus Q2, CMI market growth of 45% year-over-year, and new-to-brand share close to 45% after eight months on market; cash and investments totaled $1.6 billion.

5 source passages
Cytokinetics team of Isaac Chicanover, CBO, Steve Heitner, CMO, Jeff Lotz, U.S. Sales and Ops VP, and then Sung Lee CFO. Revenue was up 76% versus Q2. CMI market, year-over-year growth of 45%. we've only been on the market for eight months when we got close to 45% NBRX share. We ended the last quarter with $1.6 billion in cash and investments. Open the document at this passage
Nov 4
Earnings call
Mycorso revenue grows 76%; NHCM expansion on track

Cytokinetics reported Mycorso Q3 net revenue of $44.5 million, up 76% from Q2, and remains on track to submit an FDA supplemental NDA for NHCM this quarter, with an FDA decision on MAPLE HCM data scheduled for November 14th.

Read from the first part of this long document
4 source passages
Welcome to the Cytokinetics Q3 2026 Earnings Call. In the third quarter, Mycorso generated $44.5 million in net revenue, up 76% from Q2. Based on these results, we're on track to submit a supplemental NDA to FDA this quarter and an application to the EMA in early 2027. Our SNDA based on MAPLE HCM remains under review with a Vidufa date of November 14th. Open the document at this passage
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
MYQORZO generates 74,630 thousand dollars in product revenue

Cytokinetics reported 74,630 thousand dollars in net product revenue for the nine months ended September 30, 2026; positive ACACIA-HCM results support a planned fourth quarter 2026 nHCM filing.

Revenue $47.56M ▲ 2356.5% Net loss $190.07M Diluted EPS -$1.37
Read from the MD&A section
5 source passages
Net product revenue | 44,507 | — | 44,507 | 74,630 | — | 74,630 *All values are in US Dollars. Revenues for the three and nine months ended September 30, 2026 and 2025, were as follows (in thousands): ACACIA-HCM met both dual primary endpoints, demonstrating statistically significant improvements from baseline to Week 36 compared to placebo in both Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ) and maximal exercise performance (pVO2). Based on the positive results from ACACIA-HCM, we plan to submit a supplemental NDA to the FDA for aficamten for the treatment of adult patients with symptomatic nHCM in the fourth quarter of 2026. Open the document at this passage
Nov 4
Current report 8-K
MYQORZO net product revenue reaches $44.5 million

Cytokinetics reported third-quarter 2026 revenue of $47.6 million, including $44.5 million in MYQORZO net product revenue, and expects to submit a Supplemental New Drug Application for aficamten in non-obstructive HCM in Q4 2026.

Financial results
3 source passages
Total revenues for the third quarter of 2026 were $47.6 million, compared to $1.9 million for the same period in 2025. $44.5 million MYQORZO net product revenue, inclusive of $43.1 million from the U.S. and $1.4 million from Europe reflecting product revenue in Germany, and We expect to file a Supplemental New Drug Application (NDA) for nHCM in Q4 2026 and a Type II Variation in the European Union in early 2027. Open the document at this passage
Aug 28
Current report 8-K
Other events AI summary on its way
Aug 13
Current report 8-K
Other events AI summary on its way
Aug 6
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $28.62M ▼ 57.1% Net loss $198.76M Diluted EPS -$1.50
May 8
Current report 8-K Events of May 6
Other events AI summary on its way
May 5
Current report 8-K
Other events AI summary on its way
May 5
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $19.36M ▲ 1125.8% Net loss $206.03M Diluted EPS -$1.67
Apr 17
Proxy statement DEF 14A Meeting May 27, 2026
Proxy statement AI summary on its way
Feb 26
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $88.04M ▲ 376.6% Net loss $784.96M Diluted EPS -$6.54
Feb 17
Current report 8-K
Other events AI summary on its way
2025
Aug 7
Quarterly report 10-Q FY2025 Q2, ended Jun 30
Quarterly report for FY2025 Q2
Revenue $66.77M ▲ 26714.9% Net loss $134.37M Diluted EPS -$1.12
Showing 1–50 of 270 documents
Key facts CIK 1061983 CUSIP 23282W605 13F (30d) 480 filings 440 filers Visit website Investor relations